restructuring news from FierceBiotech
News
Ailing GlaxSmithKline to axe 350 R&D workers
In an effort to shake up an organization that has produced few major advances recently, GlaxoSmithKline announced Read more...
Novartis restructures its development strategy
Novartis CEO Daniel Vasella (photo) tells the Wall Street Journal that he knew Novartis had become too big and too Read more...
Going, going... Trimeris winds down ops
Faced with a patent fight that has frustrated efforts to find a buyer, Trimeris has begun to hand back out $80 million in cash as it winds down its operations. The Trimeris board has authorized Read more...
Esperion gets second shot as an independent drugmaker
After getting squashed in Pfizer's restructuring crunch, Esperion Therapeutics is reopening this week. The company, which specializes in cardiovascular and metabolic disease work, is hiring about 10 Read more...
Valeant chops workforce in restructuring
In an effort to bring expenses in line with revenues, Valeant is cutting 130 workers in the U.S. and Mexico. In addition, headcount will be further reduced by 1,250 positions as it divests its Read more...
Novartis CEO: Deals possible in diagnostics, vaccines
Novartis AG CEO Daniel Vasella (photo) concedes that his company is going through a rough stage, but insists that a Read more...
Keryx triggers big shakeup to counter trial fiasco
Less than a month after seeing its lead drug candidate go down in flames in a late-stage trial, Keryx Read more...
Novartis discovery chief departs in management shakeup
Restructuring under the gun of new generics and after being slammed by regulatory defeats, Novartis is bidding adieu to James Shannon, its chief of global drug development. In his place Novartis has Read more...
Kosan axes staffers (again), scouts for partners
Kosan Biosciences is laying off more than a third of its 91 workers as the developer concentrates its resources around its lead cancer therapies in a restructuring that has also shuffled its newly Read more...
PDL axes 260 and takes itself off the market
With no "firm" buyout offers coming in, PDL BioPharma has decided to axe 260 workers--on top of the 320 Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends